Back to results
US 10,752,901 B2Granted
Inhibition of ferrochelatase as an antiangiogenic therapy
AssigneeIndiana University Research and Technology Corporation
InventorsTimothy Corson, Halesha Basavarajappa
Life of this patent
Estimating the term…
Abstract
Methods for treating angiogenesis-mediated diseases are disclosed. More particularly, the present disclosure relates to methods of inhibiting ferrochelatase as an antiangiogenic therapy.
Claims11
A method consisting of
- (a) steps for inhibiting ocular angiogenesis in an individual in need thereof, wherein the steps consist of administering an agent to the individual in order to inhibit ferrochelatase in the individual, the agent being selected from the group consisting of N-methylprotoporphyrin (NMPP);
- griseofulvin;
- antisense RNA;
- an agent for RNA silencing or an agent for RNA interference (RNAi) targeting ferrochelatase (FECH) RNA;
- an agent for CRISPR/Cas9-mediated genetic ablation of ferrochelatase (FECH) DNA;
- an agent for Zinc-finger nuclease-mediated genetic ablation of ferrochelatase (FECH) DNA;
- and combinations thereof, and optionally, administering one or more additional agents selected from the group consisting of ranibizumab;
- bevacizumab;
- aflibercept;
- pegpleranib;
- squalamine ((1S,2S,5S,7R,9R,10R,11S,14R,15R)-N- {3-[(4-aminobutyl)amino]propyl }-9-hydroxy-2,15-dimethyl-14-[(R2R,5R)-6-methyl-5-(sulfooxy)heptan-2- yl]tetracyclo[8.7.0.0∧{2,7 }.0 {11,15 }heptadecan-5-aminium);
- vorolanib;
- PAN-90806;
- TNP470;
- fumagillin (2E,4E,6E,8E)-10-{[R3R,4S,5S,6R)-5-methoxy-4-[(2R)-2-methyl-3-(3-methylbut-2- enyl)oxiran-2-yl]-1-oxaspiro[2,5]octan-6-yl]oxy}-10-oxodeca-2,4,6,8-tetraenoic acid);
- pigment epithelium derived factor (PEDF);
- endostatin;
- angiostatin;
- anecortave acetate;
- triamcinolone ((11β,16α)-9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione);
- and combinations thereof, wherein when the agent is griseofulvin, it is administered to achieve an intravitreal concentration of 10 μM to 500 μM of griseofulvin, and
- (b) simultaneously administering one or more pharmaceutically acceptable carriers.
19 more elements
A method consisting of
- (a) steps for treating ocular neovascular eye disease in an individual in need thereof, wherein the steps consist of administering an agent to the individual in order to inhibit ferrochelatase in the individual, the agent being selected from the group consisting of N- methylprotoporphyrin (NMPP);
- griseofulvin;
- antisense RNA;
- an agent for RNA silencing or an agent for RNA interference (RNAi) targeting ferrochelatase (FECH) RNA;
- an agent for CRISPR/Cas9-mediated genetic ablation of ferrochelatase (FECH) DNA;
- an agent for Zinc-finger nuclease-mediated genetic ablation of ferrochelatase (FECH) DNA;
- and combinations thereof, and optionally, administering one or more additional agents selected from the group consisting of ranibizumab;
- bevacizumab;
- aflibercept;
- pegpleranib;
- squalamine ((1S ,2S ,5S ,7R,9R,10R,11S,14R,15R)-N-{3-[(4-aminobutyl)amino]propyl}-9-hydroxy-2,15- dimethyl-14-{(2R,5R)-6-methyl-5-(sulfooxy)heptan-2- yl]tetracyclo[8.7.0.0∧{2,7}.0∧{11,15 }heptadecan-5-aminium);
- vorolanib;
- PAN-90806;
- TNP470;
- fumagillin (2E,4E,6E,8E)-10-{[R3R,4S,5S,6R)-5-methoxy-4-[(2R)-2-methyl-3-(3-methylbut-2- enyl)oxiran-2-yl]-1-oxaspiro[2,5]octan-6-yl]oxy}-10-oxodeca-2,4,6,8-tetraenoic acid);
- pigment epithelium derived factor (PEDF);
- endostatin;
- angiostatin;
- anecortave acetate;
- triamcinolone ((11β,16)-9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione);
- and combinations thereof, wherein when the agent is griseofulvin, it is administered to achieve an intravitreal concentration of 10 μM to 500 μM of griseofulvin, and
- (b) simultaneously administering one or more pharmaceutically acceptable carriers.
19 more elements
Dependencies are inferred from the claim text.